Objective: To investigate prospectively the insulin dose requirements of Chinese patients with type 2 diabetes mellitus treated with either multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII) therapy during a 2-week therapeutic intervention. Methods: Patients with type 2 diabetes mellitus were randomly assigned to MDI or CSII therapy. The effects of the two treatment methods were determined based on blood glucose parameters, total daily insulin dose and rates of hypoglycaemia. Results: A total of 609 patients were enrolled in the study. Glycaemic goals were achieved after a mean AE SD of 6.90 AE 2.10 and 5.44 AE 2.22 days' treatment in the MDI and CSII groups, respectively. Once stabilized, the mean AE SD total daily insulin doses were 37.12 AE 10.19 IU and 32.58 AE 8.78 IU for the MDI and CSII groups, respectively. Once stabilized, the mean AE SD total basal and bolus doses were 19.46 AE 7.95 IU/day and 17.66 AE 3.53 IU/day for the MDI group, and 22.79 AE 7.55 IU/ day and 9.81 AE 2.64 IU/day for the CSII group, respectively. There were significant differences in the total, basal and bolus insulin doses between the two groups. Conclusion: CSII therapy may be considered as an effective method to achieve good glycaemic control in Chinese patients with type 2 diabetes mellitus.
Introduction
Type 2 diabetes mellitus is characterized by the progressive loss of functional insulinproducing b-cells and the persistence of insulin resistance. 1 The deterioration of b-cell function has been recognized as a major problem in Chinese patients with type 2 diabetes mellitus, 2 resulting in insulin treatment being utilized as the major therapy. At present, although substantial progress has been made in insulin preparation and medication, insulin administered via subcutaneous injection still falls short of what is achieved by physiologically-secreted insulin. Furthermore, insulin therapy can cause hypoglycaemia, weight increase and iatrogenic hyperinsulinaemia, all of which may increase the risk of vascular disease and insulin resistance. 3, 4 Therefore, greater attention should be given to the insulin dose used in the treatment of patients with type 2 diabetes mellitus.
It has been reported that patients with type 1 diabetes mellitus receiving continuous subcutaneous insulin infusion (CSII) need a lower dose of insulin, compared with those receiving multiple daily injections (MDI). [5] [6] [7] Evidence suggests that CSII also appears to be a good alternative for the treatment of patients with type 2 diabetes mellitus who do not respond to MDI regimens. 8 In China, neutral protamine hagedorn (NPH)-based MDI and CSII methods for glycaemic control are routinely used for hospitalized patients with type 2 diabetes mellitus. However, there are insufficient numbers of relevant studies discussing the optimal insulin dose for Chinese patients with type 2 diabetes mellitus. Therefore, this study investigated the insulin dose requirements of hospitalized Chinese patients with type 2 diabetes mellitus who were treated with MDI or CSII therapy for 2 weeks. 
Patients and methods Patients

Inclusion criteria
The diagnosis of type 2 diabetes mellitus was established on the basis of the 1999 Diabetes Diagnostic Criteria of the World Health Organization. 9 Patients were hospitalized for insulin therapy due to poor glycaemic control. The inclusion criteria were as follows: (i) diabetes symptoms (e.g. polyuria, polydipsia and unexplained weight loss) plus a random venous plasma glucose concentration >11.1 mmol/l or a fasting plasma glucose concentration >7.0 mmol/l (whole blood >6.1 mmol/l), or 2-h plasma glucose concentration >11.1 mmol/l at 2 h after 75 g anhydrous glucose in an oral glucose tolerance test (2-h PBG); (ii) with no symptoms, diagnosis was not based on a single glucose determination but required confirmatory plasma venous determination. At least one additional glucose test result on another day (fasting, from a random sample or from the 2-h post-glucose load) with a value in the diabetic range was essential. If the fasting or random values were not diagnostic, the 2-h value was used.
Exclusion criteria
The exclusion criteria were as follows: (i) patients prescribed other oral hypoglycaemic agents, except for metformin; (ii) patients with acute complications such as diabetic ketoacidosis, hyperglycaemic hyperosmolar status and diabetic lactic acidosis, severe or significant hepatic or renal impairment, pregnancy, malignancy, or acute infection; (iii) late-onset type 1 diabetes as indicated by a positive result for islet-cell antibodies, glutamic acid decarboxylase antibodies or tyrosine phosphatase antibodies, and a decrease in the serum C-peptide level.
Groups and treatment
Patients were randomly divided into either the MDI or CSII group based on their hospitalization number, using a random allocation sequence (generated using a random-number table). Odd numbers were assigned to the MDI group; even numbers were assigned to the CSII group.
The initial insulin dose for all study participants was 0.3-0.4 IU/kg per day, irrespective of the route of administration. The patients in the MDI group were injected subcutaneously (s.c.) with short-acting human insulin (biosynthetic human insulin; Novo Nordisk, Bagsvaerd, Denmark) before meals, three times daily, as well as receiving NPH insulin s.c. twice-daily (Novo Nordisk). The initial NPH dose accounted for 60% of the total daily dose, and the short-acting human insulin accounted for the remaining 40%. Patients in the CSII group were treated with insulin aspart (Novo Nordisk), using Medtronic (Northridge, CA, USA) insulin pumps. In the CSII group, the initial basal dose accounted for 60% of the total daily amount, and was divided into four periods: 00:00-04:00 h, 04:00-09:00 h, 09:00-21:00 h, 21:00-24:00 h. The pre-meal dose accounted for the remaining 40% and was distributed into three pre-meal doses. These treatment regimens were undertaken for 2 weeks.
Blood glucose was monitored by fingerstick blood samples eight times per day (before the three meals and 2 h later, and at 22:00 h and 03:00 h) using a stable blood glucose monitoring device from LifeScan (Johnson & Johnson, Milpitas, CA, USA). Each patient's diet was adjusted according to the Chinese Guidelines for type 2 diabetes mellitus (reference/source not available). The basal insulin dose was preferentially adjusted to control the blood glucose level when the pre-meal blood glucose was >9 mmol/l or the postprandial blood glucose was <6 mmol/l. 10, 11 After achieving stabilized glycaemic control for 3 days, the daily insulin dose was adjusted when the pre-meal and postprandial glucose levels were <7.00 mmol/l and 11.10 mmol/l, respectively.
Hypoglycaemia was deEned as blood glucose 3.9 mmol/l and the symptoms of hypoglycaemia were resolved by the administration of oral carbohydrates, or a decrease of basal insulin or regular insulin doses based on the pre-meal and postprandial glucose levels. Unconfirmed symptomatic hypoglycaemia, nocturnal hypoglycaemic episodes and severe hypoglycaemic episodes were not specifically recorded.
Clinical measurements
Baseline clinical and demographic data for all of the study participants were collected from the medical records. Body mass index (BMI) was calculated as weight (kg)/height (m 2 ). Venous blood samples were obtained from all of the participants after 8-h fasting and treated separately. All samples for glycosylated haemoglobin (HbA 1c ) determination were anticoagulated with 1.8 mg/ml ethylenediaminetetra-acetic acid and tested using an autoanalyser (D-10 TM Hemoglobin Testing System; BIO-RAD, Hercules, CA, USA). Additional blood samples were clotted at room temperature for 15-20 min and then serum was obtained by centrifugation at >1000 g for 15 min at 2-8 C. These serum samples were used for the determination of fasting serum C-peptide levels, using an ADVIA Centaur Õ CP Immunoassay System (Siemens Healthcare, Erlangen, Germany). Capillary whole-blood samples collected after 8-h fasting were used for the determination of fasting blood glucose (FBG) concentrations using a Contour Õ blood glucose meter (Bayer, Whippany, NJ, USA).
Statistical analyses
All statistical analyses were performed using the SPSS Õ statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows Õ . Quantitative data were expressed as mean AE SD. Variables were compared between the MDI and CSII groups using an independent Student's t-test for continuous variables and 2 -test for categorical variables. A P-value < 0.05 was considered statistically significant.
Results
A total of 609 Chinese patients with type 2 diabetes mellitus (328 male; 281 female) were enrolled in the study; 303 (159 male; 144 female) were randomized to the MDI group and 306 (169 male; 137 female) were randomized to the CSII group (Figure 1 ). There were 108 (35.6%) and 110 (35.9%) newly diagnosed patients who had not received prior insulin treatment in the MDI and CSII groups, respectively. There were no significant differences in the baseline age, sex distribution, proportion of newly diagnosed patients, duration of diabetes, BMI, HbA 1c , FBG, 2-h PBG and fasting serum C-peptide levels between the MDI and CSII groups ( In the CSII group, 149 patients received insulin therapy alone and 157 received insulin in combination with metformin (mean AE SD insulin dose: 0.48 AE 0.17 IU/kg per day; mean AE SD total daily insulin dose: 32.57 AE 8.78 IU). The mean AE SD total daily basal and bolus insulin doses were 22.79 AE 7.55 IU and 9.81 AE 2.64 IU, respectively (69.03 AE 7.00% and 30.97 AE 7.00% of the total daily dose, respectively). There were significant differences in the total, basal, and bolus insulin doses between the two groups (P < 0.01; Figure 2 ; Table 2 ). The incidence of hypoglycaemia was 5.94% (18/303) in the MDI group and 1.63% (5/306) in the CSII group (P < 0.01). There were no serious adverse events recorded.
Discussion
Many studies have demonstrated that CSII therapy is more effective than MDI therapy in the treatment of patients with type 1 diabetes mellitus because CSII therapy can reduce the insulin dose required to achieve optimal glycaemic control. 5, 6, [12] [13] [14] In the present study, results showed that CSII therapy could also significantly reduce the total daily insulin dose compared with MDI therapy in Chinese patients with type 2 diabetes mellitus. The incidence of hypoglycaemia during CSII therapy was also significantly lower than that during MDI therapy.
Studies have shown that short-acting insulin analogues improve glycaemic control without increasing insulin dose in patients with type 2 diabetes mellitus, meaning that they can provide the same degree of glycaemic control with lower doses of insulin. 15, 16 Research has also focused on the drug delivery method. For example, Phillip et al. 17 showed that the initial insulin dose (IU/kg) in MDI therapy, in patients with type 1 diabetes mellitus, was significantly reduced after switching to CSII therapy. In contrast, a meta-analysis of insulin replacement in patients with type 2 diabetes mellitus found that, compared with MDI, there was no difference in the daily insulin dose with CSII. 18 Similarly, a study carried out in Indian patients with type 2 diabetes mellitus did not show a significant difference in the total daily insulin dose between MDI and CSII methods. 19 In this present study, the results showed that the mean AE SD insulin dose per unit body weight for the MDI group (0.58 AE 0.18 IU/kg per day) was significantly higher than that for the CSII group (0.48 AE 0.17 IU/kg per day; P < 0.01), which suggests that compared with CSII therapy, the regulation of the basal dose with MDI therapy was not optimal. These data therefore indicate that CSII therapy may be more effective than MDI therapy for Chinese patients with type 2 diabetes mellitus.
Postprandial blood glucose is affected by three factors: FBG, glycogen output and the absorption of intestinal glucose. In general, . Insulin dose distribution of Chinese patients with type 2 diabetes mellitus (n ¼ 609), randomized to receive either multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII) therapy for 2 weeks. In order to achieve stabilized glycaemic control, patients were treated for a mean AE SD of 6.90 AE 2.10 days in the MDI group and 5.44 AE 2.22 days in the CSII group. Measurements used for this analysis were performed after a further 3 days' glucostasis. Data presented as mean AE SD. *P < 0.01 versus the MDI group; independent Student's t-test. the increase of 2-h PBG is led by the elevation of glycogen output and absorption of gastrointestinal glucose. In healthy subjects and patients with type 2 diabetes mellitus, the gastrointestinal absorption of glucose is analogous, 20 and one of the roles of basal insulin is to restrain the output of glycogen. 21 Basal insulin not only reduces FBG and pre-meal blood glucose, but also partially restrains postprandial hyperglycaemia. When basal insulin treatment is used to reduce 2-h PBG, a lower dose of pre-meal insulin is required as a supplement to control 2-h PBG. However, pre-meal insulin treatment only restrains the glycogen output and absorption-related increase of glucose. The Henry activity curve for insulin suggests that the higher the concentration of pre-meal insulin, the greater its effect on reducing non-meal blood glucose, and the stronger the 'tail effect' on pre-meal glucose levels. 22 A lower pre-meal dose of insulin can reduce the additive effect of the basal dose and thereby avoid modulating the basal dose. Suzuki et al. 23 showed that increasing the basal insulin dose might be a useful way to control FBG and HbA 1c in patients with type 2 diabetes mellitus whose basal insulin was switched from NPH insulin to insulin glargine. In this present study, the total daily basal insulin dose was significantly higher in the CSII group than in the MDI group, demonstrating the advantage of CSII therapy. In this present study, at least during a short-term 2-week therapeutic intervention, patients with type 2 diabetes mellitus treated with MDI showed a significantly higher total daily insulin requirement, a longer duration to achieve the target glycaemic control, and a higher incidence of hypoglycaemia compared with patients treated with CSII therapy. Therefore, CSII therapy may be considered as an effective method to achieve good glycaemic control, with a lower total daily insulin dose due to an In order to achieve stabilized glycaemic control, patients were treated for a mean AE SD of 6.90 AE 2.10 days in the MDI group and 5.44 AE 2.22 days in the CSII group. Measurements used for the analysis of FBG, 2-h PBG and insulin dose data were performed after a further 3 days' glucostasis.
Incidence of hypoglycaemia was recorded over the 2-week treatment period. a Glycaemic goals: pre-meal glucose and postprandial glucose, <7.00 mmol/l and 11.10 mmol/l, respectively. *P < 0.01 versus MDI group; categorical variables analysed using 2 -test; continuous variables analysed using independent Student's t-test. FBG, fasting blood glucose; PBG, postprandial blood glucose.
